Cancer vaccination by electro-gene-transfer

Expert Review of Vaccines

Volumn 12, Issue 10, 2013, Pages 1127-1137

  Aurisicchio, Luigi ^a,b   Mancini, Rita ^c   Ciliberto, Gennaro ^d  

^a Istituto di Ricerche Genetiche Gaetano Salvatore Biogem sc arl   (Italy)

^b University la Sapienza ^*

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

clinical trials; DNA and RNA vaccines ogeneticvaccination; immunotherapy of cancer; in vivo electroporation

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; DNA FRAGMENT; DNA VACCINE; EPITOPE; GAMMA INTERFERON; GTDOM PSMA(27); IDN 6439 RHUT; IMMUNOGLOBULIN G; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; NAKED DNA; NUCLEIC ACID; NUCLEOSIDE ANALOG; PLASMID DNA; PROSTATE SPECIFIC MEMBRANE ANTIGEN; SCIB1; T LYMPHOCYTE ANTIGEN; TELOMERASE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 930; V 932; V 934; V 935; V934; VGX 3100;

CANCER IMMUNIZATION; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DEVICES; DRUG DELIVERY DEVICE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; ELECTRO GENE TRANSFER; ELECTROPORATION; GENE TRANSFER; HEAD AND NECK CANCER; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MELANOMA; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UTERINE CERVIX CANCER; VACCINATION;

CANCER VACCINES; ELECTROPORATION; HUMANS; NEOPLASMS; TRANSFORMATION, GENETIC; VACCINATION; VACCINES, DNA;

EID: 84886084027     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2013.836903     Document Type: Review

References (74)

1. Frohlich MW. Sipuleucel-T for the treatment of advanced prostate cancer. Semin. Oncol. 39(3), 245-252 (2012).
2. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
3. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann. Oncol. 23(Suppl. 8), viii6-9 (2012).
4. Hale DF, Clifton GT, Sears AK et al. Cancer vaccines: should we be targeting patients with less aggressive disease Expert Rev. Vaccines 11(6), 721-731 (2012).
5. Aurisicchio L, Ciliberto G. Genetic cancer vaccines: current status and perspectives. Expert Opin. Biol. Ther. 12(8), 1043-1058 (2012).
6. Locher C, Conforti R, Aymeric L et al. Desirable cell death during anticancer chemotherapy. Ann. NY Acad. Sci. 1209, 99-108 (2010).
7. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 12(4), 253-268 (2012).
8. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic inflammation: a magic bullet Science 339(6117), 286-291 (2013).
9. Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol. Immunother. 62(2), 203-16 (2013).
10. Vesely MD, Kershaw MH, Schreiber RD et al. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235-271 (2011).
11. Porzia A, Lanzardo S, Citti A et al. Attenuation of PI3K/Akt-mediated tumorigenic signals through PTEN activation by DNA vaccine-induced anti-ErbB2 antibodies. J. Immunol. 184(8), 4170-4177 (2010).
12. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 356(6365), 152-154 (1992).
13. Liu MA. DNA vaccines: An historical perspective and view to the future. Immunol. Rev. 239, 62-84 (2011).
14. Aurisicchio L, Peruzzi D, Conforti A et al. Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin. Cancer Res. 15, 1575-1584 (2009).
15. Peruzzi D, Mesiti G, Ciliberto G et al. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 28, 1201-1208 (2010).
16. Liu MA, Ulmer JB. Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55, 25-40 (2005). (Pubitemid 43580697)
17. Kennedy JS, Co M, Green S et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26(35), 4420-4424 (2008)
18. Trimble CL, Peng S, Kos F et al. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin. Cancer Res. 15(1), 361-367 (2009).
19. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: prospects for success. Curr. Opin. Immunol. 23(3), 421-429 (2011).
20. Andrè F, Mir LM. DNA electrotransfer: Its principles and an updated review of its therapeutic applications. Gene Ther. 11, S33-42 (2004). (Pubitemid 39359445)
21. Gothelf A, Gehl J. What you always needed to know about electroporation based DNA vaccines. Hum. Vaccin. Immunother. 8(11), 1694-1702 (2012).
22. Neumann E, Kakorin S, Toensing K. Fundamentals of electroporative delivery of drugs and genes Bioelectrochem. Bioenerg. 48(1), 3-16 (1999). (Pubitemid 29150357)
23. Lurquin PF. Gene transfer by electroporation. Mol. Biotechnol. 7(1), 5-35 (1997) (Pubitemid 127499079)
24. Fattori E, La Monica N, Ciliberto G et al. Electro-gene-transfer: a new approach for muscle gene delivery. Somat. Cell. Mol. Genet. 27(1-6), 75-83 (2002).
25. Lee RC, Canaday DJ, Hammer SM. Transient and stable ionic permeabilization of isolated skeletal muscle cells after electrical shock. J. Burn. Care Rehabil. 14(5), 528-540 (1993).
26. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene. Ther. 6(4), 508-514 (1999). (Pubitemid 29192659)
27. Mir LM, Bureau MF, Gehl J et al. High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. Natl Acad. Sci. USA 96(8), 4262-4267 (1999). (Pubitemid 29190324)
28. Rizzuto G, Cappelletti M, Mennuni C et al. Electro Gene-transfer results in a high level transduction of rat skeletal muscle and corrects anaemia of renal failure. Hum. Gene. Ther. 11, 1891-1900 (2000).
29. Babiuk S, Baca-Estrada ME, Foldvari M et al. Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J. Biotechnol. 110(1), 1-10 (2004). (Pubitemid 38510249)
30. Liu J, Kjeken R, Mathiesen I et al. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J. Virol. 82(11), 5643-5649 (2008). (Pubitemid 351705271)
31. Cappelletti M, Zampaglione I, Rizzuto G et al. Gene electro-transfer improves transduction by modifying the fate of intramuscular plasmid DNA. J. Gene. Med. 5, 324-332 (2003). (Pubitemid 40310384)
32. Capone S, Zampaglione I, Vitelli A et al. Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J. Immunol. 177, 7462-7471 (2006). (Pubitemid 44715117)
33. Luckay A, Sidhu MK, Kjeken R et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 81(10), 5257-5269 (2007). (Pubitemid 46744435)
34. Reed SD, Li S. Electroporation advances in large animals. Curr. Gene. Ther. 9(4), 316-326 (2009).
35. Fowler V, Robinson L, Bankowski B et al. A DNA vaccination regime including protein boost and electroporation protects cattle against foot-and-mouth disease. Antiviral. Res. 94(1), 25-34 (2012).
36. Durieux AC, Bonnefoy R, Busso T et al. In vivo gene electrotransfer into skeletal muscle: effects of plasmid DNA on the occurrence and extent of muscle damage. J. Gene. Med. 6(7), 809-816 (2004). (Pubitemid 40228097)
37. Diaz CM, Chiappori A, Aurisicchio L et al. Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors. J. Transl. Med. 11, 62 (2013).
38. Hirao LA, Wu L, Khan AS et al. Intradermal/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 26(3), 440-448 (2008).
39. Ansaldi F, Durando P, Icardi G. Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement. Expert Opin. Biol. Ther. 11(3), 415-427 (2011).
40. Broderick KE, Shen X, Soderholm J et al. Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene. Ther. 18(3), 258-265 (2011).
41. Hutnick NA, Myles DJ, Ferraro B et al. Intradermal DNA vaccination enhanced by low-current electroporation improves antigen expression and induces robust cellular and humoral immune responses. Hum. Gene. Ther. 23(9), 943-950 (2012).
42. Quaglino E, Mastini C, Amici A et al. A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins. Cancer Res. 70(7), 2604-2612 (2010).
43. Cipriani B, Fridman A, Bendtsen C et al. Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy. Hum. Gene. Ther. 19(7), 670-680 (2008). (Pubitemid 352009912)
44. Vittes GE, Harden EL, Ottensmeier CH et al. DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. Eur. J. Immunol. 41(8), 2447-2456 (2011).
45. Low L, Mander A, McCann K et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum. Gene. Ther. 20(11), 1269-1278 (2009).
46. Chudley L, McCann K, Mander A et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol. Immunother. 61(11), 2161-2170 (2012).
47. Tjelle TE, Salte R, Mathiesen I et al. A novel electroporation device for gene delivery in large animals and humans. Vaccine 24(21), 4667-4670 (2006).
48. Facciabene A, Aurisicchio L, Elia L et al. Vectors encoding carcinoembryonic antigen fused to the B subunit of heat-labile enterotoxin elicit antigen-specific immune responses and antitumor effects. Vaccine 26(1), 47-58 (2007).
49. Bagarazzi ML, Yan J, Morrow MP et al. Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci. Transl. Med. 4(155), 155ra138 (2012).
50. Weide B, Carralot JP, Reese A et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J. Immunother. 31(2), 180-188 (2008).
51. Rittig SM, Haentschel M, Weimer KJ et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol. Ther. 19(5), 990-999 (2011).
52. Fotin-Mleczek M, Duchardt KM, Lorenz C et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011).
53. Fotin-Mleczek M, Zanziger K, Heindereich R et al. Highly potent MRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J. Gene. Med. 14(6),428-439 (2012).
54. Berglund P, Smerdou C, Fleeton MN et al. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 16(6), 562-565 (1998). (Pubitemid 28269815)
55. Nordström EK, Forsell MN, Barnfield C et al. Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J. Gen. Virol. 86(Pt 2), 349-354 (2005). (Pubitemid 40227946)
56. Lundstrom K. Generation of recombinant alphaviral vectors. Cold Spring Harb. Protoc. 2012(7), 825-831 (2012).
57. Karlsson GB, Liljeström P. Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors. Methods Mol. Biol. 246, 543-557 (2004).
58. Geall AJ, Verma A, Otten GR et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109(36), 14604-14609 (2012).
59. Knudsen ML, Mbewe-Mvula A, Rosario M et al. Superior induction of T cell responses to conserved HIV-1 regions by electroporatedalphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J. Virol. 86(8), 4082-4090 (2012).
60. Johansson DX, Ljungberg K, Kakoulidou M et al. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS ONE 7(1), e29732 (2012).
61. Ranasinghe C, Ramshaw IA. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev. Vaccines 8(9), 1171-1181 (2009).
62. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21(3), 346-351 (2009).
63. Capone S, Reyes-Sandoval A, Naddeo M et al. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates. Vaccine 29(2), 256-265 (2010).
64. Sheehy SH, Duncan CJ, Elias SC et al. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. Mol. Ther. 20(12), 2355-2368 (2012).
65. Ratto-Kim S, Currier JR, Cox JH et al. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens. PLoS ONE 7(9), e45840 (2012).
66. Tan WG, Jin HT, West EE et al. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J. Virol. 87(3), 1359-1372 (2013).
67. Mennuni C, Calvaruso F, Facciabene A et al. Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA. Int. J. Cancer 117, 444-455 (2005). (Pubitemid 41429568)
68. Aurisicchio L, Mennuni C, Giannetti P et al. Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int. J. Cancer 120, 2290-2300 (2007). (Pubitemid 46642113)
69. Mori F, Giannetti P, Peruzzi D et al. A therapeutic cancer vaccine targeting carcinoembryonic antigen in intestinal carcinomas. Hum. Gene. Ther. 20, 125-136 (2009).
70. Facciabene A, Aurisicchio L, Elia L et al. DNA and adenoviral vectors encoding carcinoembryonic antigen fused to immunoenhancing sequences augment antigen-specific immune response and confer tumor protection. Hum. Gene. Ther. 17, 81-92 (2006). (Pubitemid 43100517)
71. Mennuni C, Ugel S, Mori F et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res. 68, 9865-9874 (2008).
72. Fattori E, Aurisicchio L, Zampaglione I et al. ErbB2 genetic cancer vaccine in nonhuman primates: relevance of single nucleotide polymorphisms. Hum. Gene. Ther. 20(3),253-265 (2009).
73. Peruzzi D, Gavazza A, Mesiti G et al. A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol. Ther. 18(8), 1559-1567 (2010).
74. Gavazza A, Lubas G, Fridman A, et al. Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum. Gene. Ther. 24(8), 728-738 (2013)